Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05661565 Not yet recruiting - Clinical trials for Study the Relationship Between Insulin Resistance With Hormonal and Ovarian Morphological Characteristics in Patients With Polycystic Ovarian Syndrome

Correlation of Insulin Resistance With Hormonal and Ovarian Morphological Characteristics in Patients With Polycystic Ovarian Syndrome

Start date: January 1, 2023
Phase:
Study type: Observational

We designed a study to determine if ovarian volume (OV) and/or follicle number (FN) are independently associated with abnormal metabolic findings in women diagnosed with PCOS. We hypothesized that ovarian morphology but not follicle number would be associated with a significantly higher odds of hyperinsulinemia among women with PCOS.

NCT ID: NCT05659199 Not yet recruiting - Clinical trials for Chronic Pelvic Pain Syndrome

Extracorporeal Shockwave and Myofascial Release Therapy in Chronic Pelvic Pain Syndrome

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The primary aims of this research are three folds: (1) To identify more relatively effective interventions for improving pain symptoms in CP/CPPS patients. (2) To ascertain the correlation between PFM elastic modulus and tenderness symptoms. This may find a more objective method of assessing efficacy. (3) To determine the correlation between the intensity of the sympathetic response and the patient's symptoms and to explore other possible pathogenetic mechanisms.

NCT ID: NCT05655728 Not yet recruiting - Metformin Clinical Trials

Treatment With Metformin in Chinese Children With Alport Syndrome

Start date: January 3, 2023
Phase: Phase 4
Study type: Interventional

This single-center, prospective, double-blind randomized placebo-controlled trial will evaluate the efficacy and safety of metformin in Chinese children with Alport syndrome who have received (and continue to receive)) ACEi/ARB.

NCT ID: NCT05647356 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2

REFUEL PCOS
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Polycystic ovary syndrome (PCOS) affects 10% of all women, and it usually co-exists with high levels of sex hormones called androgens, such as testosterone. Women with PCOS are at increased risk of metabolic complications such as diabetes, non-alcoholic fatty liver disease, high blood pressure and heart disease. However, very little is understood about how androgen excess may drive the metabolic complications observed in women with PCOS. Skeletal muscle is an important site of energy metabolism; increasingly, it is suspected that skeletal muscle energy balance is adversely impacted by androgens, thereby driving metabolic complications. To take this theory forward, we want to investigate the effects of androgens on muscle energy metabolism. We will perform detailed metabolic testing (including blood tests and muscle biopsies) in women with PCOS before and after taking tablets that block the action of testosterone for 28 days. In addition, we will be using a gold standard technique to see how women with PCOS metabolise fat and other nutrients by measuring markers in blood and breath samples after a breakfast test meal. This clinical research will increase our understanding of the complex relationships between hormonal abnormalities and metabolic disease in women with PCOS.

NCT ID: NCT05646199 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

Start date: March 1, 2025
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period. The main question it aims to answer is: • Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS? Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly. The maximum duration of participation for the patients in the trial is 32 weeks. Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

NCT ID: NCT05638568 Not yet recruiting - Clinical trials for Bronchopulmonary Dysplasia

Fast Assessment of Surfactant Deficiency in Preterm Infants to Speed up Treatment

FAST2
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Recently the investigators have developed a point of care test (LS-test) to measure surfactant as lecithin in gastric aspirates from preterm infants. This test can be done immediately at delivery and potentially be used to guide surfactant treatment. To obtain evidence-based knowledge on harms and benefit of surfactant therapy guided by the L/S test, a randomized clinical trial with relevant clinical short-and long-term outcomes needs to be performed, which is why the FAST 2 Trial has been designed.

NCT ID: NCT05630703 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome (IBS)

Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet

FODMAP
Start date: July 2024
Phase: N/A
Study type: Interventional

The study aims to compare the effect of mindfulness-based awareness training in Irritable Bowel Syndrome (IBS) (MB-IBS-EAT) with the dietary standard of care (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet) on patient's IBS symptoms

NCT ID: NCT05625568 Not yet recruiting - Rett Syndrome Clinical Trials

Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients

Start date: March 2023
Phase: Phase 2
Study type: Interventional

This is an exploratory, Phase 2, multicenter, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, and efficacy of oral treatment with VYNT-0126 in female subjects 18-45 years of age with Rett syndrome.

NCT ID: NCT05605106 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Addiction and Acute Coronary Syndrome

Start date: December 1, 2022
Phase:
Study type: Observational

the study aims to 1. identify the effect of addiction on TIMI flow in patients presented with acute coronary syndrome. 2. identify the effect of addiction on outcomes of medical treatment of patients presenting with acute coronary syndrome. 3. identify the relation between addiction and LV function. 4. detect the effect of duration of addiction on myocardial infarction lesion and outcomes of pci.

NCT ID: NCT05597111 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS)

Start date: November 1, 2022
Phase:
Study type: Observational

Although PCOS has been known for many years, its etiology and treatment are not clearly known. The prevalence of PCOS varies between populations. It is a familial endocrinolpathology with a chronic course, multifactorial, polygenic feature seen with an average prevalence of 6-8% in women in the reproductive period.Chronic inflammation is involved in the pathophysiology of many chronic diseases. PCOS, which is a proinflammatory condition, has been associated with insulin resistance and hyperandrogenism in previous studies. Omega-3 fatty acids have anti-inflammatory, anti-thrombotic, anti-arrhythmic properties, reducing lipid levels such as serum triglyceride and LDL cholesterol, and having positive effects on the immune system. Therefore, their deficiencies include fatigue, joint pain, frequent infections, etc. is seen. Omega-6 fatty acids have the opposite effect. DHA is a member of the omega-3 fatty acids family. Dietary components play an important role in chronic inflammation. According to our literature review, there is no study that detects docosahexaenoic acid (DHA) levels in blood and cervical mucus samples in patients with PCOS. We think that we will contribute to the diagnosis and treatment processes of PCOS patients by detecting DHA levels in this study. In this study, we aim to compare the values of docosahexaenoic acid (DHA) in serum and cervical mucus samples in patients with polycystic ovary syndrome with the control group.